{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae EA IgG",
        "LIAISON\u00ae EA IgG Serum Control Set"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K162959",
    "Predicate Device Reference 510(k) Number(s)": [
        "K060204"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "LSE",
        "JJX"
    ],
    "Summary Letter Date": "October 21, 2016",
    "Summary Letter Received Date": "December 5, 2016",
    "Submission Date": "October 21, 2016",
    "Regulation Number(s)": [
        "21 CFR 866.3235"
    ],
    "Regulation Name(s)": [
        "Epstein-Barr virus serological reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Epstein-Barr virus (EBV) early antigen-diffuse [EA(D)]"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer family",
        "LIAISON\u00ae",
        "LIAISON\u00ae XL"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control Set"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON\u00ae EA IgG chemiluminescent immunoassay and serum-based control set for detection of EBV EA(D) IgG antibodies",
    "Indications for Use Summary": "Qualitative determination of specific IgG antibodies to Epstein-Barr virus early antigen-diffuse [EA(D)] in human serum, used as an aid in the diagnosis of Epstein-Barr Viral Syndrome in patients with signs and symptoms of EBV infection such as infectious mononucleosis, and as quality control samples for monitoring assay performance on the LIAISON\u00ae Analyzer family",
    "fda_folder": "Microbiology"
}